Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin

Kavindra V. Singh, George M. Weinstock, Barbara E. Murray
Kavindra V. Singh
1Center for the Study of Emerging and Reemerging Pathogens
2Division of Infectious Diseases, Department of Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George M. Weinstock
1Center for the Study of Emerging and Reemerging Pathogens
3 Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030
4Department of Microbiology and Molecular Genetics, The University of Texas Medical School at Houston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara E. Murray
1Center for the Study of Emerging and Reemerging Pathogens
2Division of Infectious Diseases, Department of Internal Medicine
4Department of Microbiology and Molecular Genetics, The University of Texas Medical School at Houston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bem.asst@uth.tmc.edu
DOI: 10.1128/AAC.46.6.1845-1850.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Enterococcus faecalis isolates are resistant to clindamycin (CLI) and quinupristin-dalfopristin (Q-D), and this is thought to be a species characteristic. Disruption of a gene (abc-23, now designated lsa, for “lincosamide and streptogramin A resistance”) of E. faecalis was associated with a ≥40-fold decrease in MICs of Q-D (to 0.75 μg/ml), CLI (to 0.12 to 0.5 μg/ml), and dalfopristin (DAL) (to 4 to 8 μg/ml) for the wild-type E. faecalis parental strain (Q-D MIC, 32 μg/ml; CLI MIC, 32 to 48 μg/ml; DAL MIC, 512 μg/ml). Complementation of the disruption mutant with lsa on a shuttle plasmid resulted in restoration of the MICs of CLI, Q-D, and DAL to wild-type levels. Under high-stringency conditions, lsa was found in 180 of 180 isolates of E. faecalis but in none of 189 other enterococci. Among 19 erm(B)-lacking Enterococcus faecium strains, 9 (47%) were highly susceptible to CLI (MIC, 0.06 to 0.25 μg/ml) and had DAL MICs of 4 to 16 μg/ml; for the remaining erm(B)-lacking E. faecium strains, the CLI and DAL MICs were 4 to >256 and 2 to >128 μg/ml, respectively. In contrast, none of 32 erm(B)-lacking E. faecalis strains were susceptible (CLI MIC range, 16 to 32 μg/ml; DAL MIC range, ≥32 μg/ml). When lsa was introduced into an E. faecium strain initially susceptible to CLI, the MICs of CLI and DAL increased ≥60-fold and that of Q-D increased 6-fold (to 3 to 6 μg/ml). Introduction of lsa into two DAL-resistant (MICs, >128 μg/ml), Q-D-susceptible (MICs, 0.5 and 1.5 μg/ml) E. faecium strains (CLI MICs, 12 and >256 μg/ml) resulted in an increase in the Q-D MICs from 3- to 10-fold (to 8 and >32 μg/ml), respectively. Although efflux was not studied, the similarity (41 to 64%) of the predicted Lsa protein to ABC proteins such as Vga(A), Vga(B), and Msr(A) of Staphylococcus aureus and YjcA of Lactococcus lactis and the presence of Walker A and B ATP-binding motifs suggest that this resistance may be related to efflux of these antibiotics. In conclusion, lsa appears to be an intrinsic gene of E. faecalis that explains the characteristic resistance of this species to CLI and Q-D.

Over the past few years, enterococci have emerged as important bacterial pathogens in nosocomial infections (12, 25-27, 40). These organisms have acquired and/or intrinsic resistance to many different antibiotics (18, 19), which poses a serious problem for the treatment of patients infected with these organisms. Studies have shown that Enterococcus faecalis, unlike E. faecium, is usually resistant to quinupristin-dalfopristin (Q-D), with MICs of 4 to ≥32 μg/ml (3, 10, 12, 35), and that both species are typically resistant to clindamycin (CLI) (12). Acquired resistance to Q-D in E. faecium has also been described, and contributing mechanisms include drug inactivation by enzymes, structural or conformational alterations in ribosomal target binding sites, and efflux of antibiotic out of cells (3, 10). In E. faecalis, however, the mechanism of resistance to Q-D has not been well studied.

We recently investigated the presence of putative transporters in E. faecalis, identified 34 possible transporter homologs, and made disruption mutants of 31 of these (8). Among these mutants were ones with increased susceptibility to novobiocin, pentamidine, daunorubicin, and norfloxacin and one, whose disrupted gene was originally designated abc-23, with reduced susceptibility to Q-D and CLI; the MICs of ∼20 other compounds were similar to those for wild-type OG1RF (8). In the present study, we have further studied this gene and its effect by comparing it with known ABC transporters, by complementing the disruption mutant and introducing the gene into E. faecium strains on a shuttle vector, and by determining its distribution among Enterococcus spp. Based on these results, we have renamed this gene lsa in recognition of its apparent role in the intrinsic resistance of E. faecalis to lincosamides (CLI) and streptogramin A (dalfopristin [DAL]).

MATERIALS AND METHODS

Bacterial strains and MIC studies.The bacteria used in this study were obtained from the collection of our laboratory, which was compiled over the past 20 years. The recipient strains and plasmids used in the study are listed in Table 1. These include E. faecalis strain OG1RF (29) and E. faecium isolates SE34 (TX1330; recovered from feces of a healthy community volunteer [7]), TX2466 (a clinical isolate [23]), and D344-S (36); the E. faecium strains were chosen because of their differing susceptibilities to CLI (MICs of 8 to 16, <0.25, and >256 μg/ml, respectively). A total of 492 isolates of enterococci, including 257 of E. faecalis, 216 of E. faecium, 6 of E. hirae, 5 of E. durans, 2 of E. casseliflavus, 2 of E. mundtii, 1 of E. gallinarum, 2 of E. solitarius, and 1 of E. raffinosus (12, 44), were used for lsa probing and/or susceptibility testing. MICs were determined by agar dilution (30, 31) or by the E test (PDM Epsilometer test; AB BIODISK North America, Inc., Piscataway, N.J.) in accordance with the manufacturer's instructions. Erythromycin (ERY), CLI, kanamycin (KAN), and chloramphenicol (CHL) were purchased from Sigma Chemical Co., St. Louis, Mo., and quinupristin, DAL, and Q-D were provided by Aventis Pharma S.A., Vitry-sur-Seine Cedex, France.

View this table:
  • View inline
  • View popup
TABLE 1.

Bacterial strains and plasmids used in this study

DNA extraction, PCR, sequencing, and cloning.DNA extraction (46) and PCRs were performed with the PCR Optimizer kit (Invitrogen, San Diego, Calif.); PCR products were analyzed by automated DNA sequencing at the Microbiology and Molecular Genetics core facility, University of Texas Medical School, Houston, Tex. Sequence analysis was done by using the BLAST network service of the National Center for Biotechnology Information. The Genetics Computer Group software package (Genetics Computer Group, Madison, Wis.) was used to compare similarities among other sequences. ClustalW, at the Baylor College of Medicine website, was used, and the GeneDoc software was used for editing and shading of sequences. Cloning was done with standard methods (42).

Disruption mutation in lsa (abc-23) of E. faecalis.The disruption mutation in strain OG1RF was created previously (8). Briefly, the disruption mutant was created by using a PCR-amplified ∼700-bp intragenic DNA fragment from E. faecalis strain V583 inserted into previously described pBluescript derivative pTEX4577 containing aph(3′)-IIIa (13, 43), resulting in pTEX5332, which was electroporated into competent cells of OG1RF and selected with KAN at 2,000 μg/ml. The resulting mutant was previously shown by PCR to have the targeted insertion of the plasmid (8). In the present study, the insertion was also confirmed by hybridizing EcoRI digests of genomic DNAs of wild-type E. faecalis OG1RF and the lsa disruption mutant with an intragenic lsa DNA probe under high-stringency conditions. In addition, the susceptibility of this mutant to quinupristin, DAL, ampicillin, tetracycline, and ERY was determined by the E test. Recombinant colonies of TX5332 (lsa disruption mutant) were further analyzed by pulsed-field gel electrophoresis (28) of SmaI-digested genomic DNA by comparison with wild-type OG1RF to confirm the host background.

Complementation of TX5332 (lsa disruption mutant).An ∼2-kb fragment (the 1,497-bp lsa ORF, ∼300 bp upstream and ∼200 bp downstream obtained from the V583 E. faecalis TIGR database) was PCR amplified from wild-type E. faecalis V583 and was first cloned into the pCR2.1 vector of the TA cloning kit. This PCR fragment was excised from vector pCR2.1 by digestion with restriction enzymes XbaI and BamHI and then recloned into shuttle vector pWM401 (47), resulting in pTEX5333. Plasmid pTEX5333 DNA was electroporated into competent cells of TX5332 (lsa disruption mutant), and selection was made on Todd-Hewitt agar (Becton Dickinson, Cockeysville, Md.) supplemented with 0.25 M sucrose, KAN at 2,000 μg/ml and CHL at 8 μg/ml. The resulting colonies were restreaked on KAN-CHL plates and analyzed for resistance to CLI, Q-D, and DAL by the E-test or agar dilution method.

Determination of the stability of the components of TX5333.Growth curves comparing wild-type OG1RF, TX5332 (the lsa disruption mutant), and TX5333 (the complemented lsa disruption mutant) were determined with and without antibiotics selective for the chromosomal disruption and/or the shuttle plasmid. Observations were made by measuring optical density at 600 nm hourly, and CFU determinations at 24 h were made on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, Mich.) with and without antibiotics. BHI broth was used to grow wild-type OG1RF; BHI and BHI-KAN were used to grow TX5332; and BHI, BHI-KAN, and BHI-KAN-CHL were used to grow TX5333.

Effect of lsa on E. faecium antibiotic resistance .Electrocompetent cells of E. faecium strains TX1330, TX2466, and D344-S were prepared as previously described (14, 20). Following electroporation of pTEX5333, selection was made on Todd-Hewitt agar supplemented with 0.25 M sucrose and CHL at 8 μg/ml. The resulting colonies were restreaked onto BHI agar-CHL plates and tested for susceptibility to CLI, Q-D, DAL, and quinupristin by the E-test or agar dilution method and also by pulsed-field gel electrophoresis (28) of SmaI-digested genomic DNA and compared to each parental E. faecium strain.

Distribution of lsa among Enterococcus spp.Three hundred sixty-nine enterococcal isolates were tested for the presence of lsa by colony lysate hybridization under high-stringency conditions with an lsa intragenic DNA probe as previously described (43). The erm(B) DNA gene probe was PCR amplified as previously described (44) and used for hybridization under high-stringency conditions. The DNA gene probes and hybridization conditions for efaAfs and aac(6′)-Iifm were the same as those used in a previous study (12).

RESULTS AND DISCUSSION

Determination of stability of components of the E. faecalis lsa disruption mutant by complementation and susceptibility testing.Testing of the complemented lsa disruption mutant (TX5333) showed that when TX5333 was grown in BHI broth or in BHI with CHL at 8 μg/ml, there was an ∼3-log reduction in the number of CFU of Kanr colonies per ml versus when this strain was grown in the presence of KAN at 2,000 μg/ml-CHL at 8 μg/ml. Because of the apparent instability of the chromosomal disruption (Kanr), the mutant was subsequently tested for susceptibility in the presence of KAN at 2,000 μg/ml in Mueller-Hinton II agar (Becton Dickinson) for TX5332 to maintain the chromosomal disruption and in Mueller-Hinton II agar with KAN at 2,000 μg/ml and CHL at 8 μg/ml to maintain the chromosomal disruption and shuttle plasmid.

The MICs determined for wild-type E. faecalis OG1RF, TX5332, and TX5333 are presented in Table 2; the MICs of ampicillin, tetracycline (data not shown), norfloxacin, ciprofloxacin, ethidium bromide, and other compounds previously tested (8) showed no difference among these strains. The lsa mutant was tested on multiple occasions and showed a >40-fold decrease in the MIC of Q-D (0.75 μg/ml) and a ≥64-fold decrease in the MICs of CLI (0.12 to 0.5 μg/ml) and DAL (4 to 8 μg/ml) versus the wild-type E. faecalis parental strain (Q-D MIC, 32 μg/ml; CLI MIC, 32 to 48 μg/ml; DAL MIC, 512 μg/ml). This indicates that lsa or some downstream function is necessary for resistance to CLI and DAL in E. faecalis. Complementation of the disruption mutant with lsa (and ∼300 bp of the upstream sequence and ∼200 bp of the downstream sequence) on a shuttle plasmid resulted in restoration of the MICs of CLI (from 0.12 to 0.5 μg/ml to 32 to 48 μg/ml), Q-D (from 0.75 μg/ml to 32 μg/ml), and DAL (from 4 to 8 μg/ml to 512 μg/ml) (Table 2). This confirms the importance of lsa, as opposed to a possibly cotranscribed downstream gene. The MIC of quinupristin was 16 μg/ml for OG1RF and the two derivatives, and the ERY MIC was 1 μg/ml. The increase in the MICs of CLI (a lincosamide) and DAL (streptogramin A) and the lack of a change in the MICs of macrolides (ERY) or quinupristin (streptogramin B) correspond to the LSA phenotype (5), and the data presented here clearly indicate the involvement of lsa in this phenotype in E. faecalis.

View this table:
  • View inline
  • View popup
TABLE 2.

MICs for E. faecalis OG1RF, TX5332 (lsa disruption mutant), and TX5333 (complemented mutant)

Effect of lsa on the antibiotic resistance of E. faecium.To determine if the 2-kb lsa region could function in a heterologous host, we selected strains of E. faecium to serve as recipients of the lsa gene by evaluating 68 E. faecium strains for susceptibility to CLI and for the presence of erm(B), since the latter influences CLI susceptibility (Table 3). While most of the isolates were erm(B)+, an interesting observation was the bimodal distribution of CLI MICs among the erm(B)-lacking E. faecium isolates. Of 19 erm(B)-lacking E. faecium isolates, 10 showed high CLI MICs (MIC, 4 to >256 μg/ml) and 9 showed low CLI MICs (MIC, 0.06 to 0.25 μg/ml). In contrast, none of the 32 erm(B)-lacking E. faecalis isolates showed low CLI MICs (MIC, 16 to 32 μg/ml). We chose three E. faecium strains (Tables 1 and 4) with different CLI and DAL susceptibilities [one of which is erm(B)+] and introduced the lsa gene on a shuttle plasmid. For the most susceptible strain (TX2466 [CLI MIC, 0.19 μg/ml; DAL MIC, 2 μg/ml; Q-D MIC, 0.5 μg/ml]), there was a marked increase in the MICs of CLI (12 μg/ml) and DAL (>128 μg/ml) and an increase to 3 to 6 μg/ml in the Q-D MIC. The ranges of the MICs of Q-D and the other agents were derived by testing on three or more different occasions. For the highly DAL-resistant (MIC, >128 μg/ml) and moderately CLI-resistant (MIC, 12 to 24 μg/ml) recipient TX1330, the MICs of DAL and CLI changed very little, if at all, after lsa was introduced but the Q-D MIC increased from 0.5 μg/ml to 6 to 8 μg/ml. The most pronounced increase in the Q-D MIC (from 3 to ≥32 μg/ml) was seen in strain D344 erm(B)+, which was initially highly DAL resistant (MIC, >128 μg/ml) and CLI resistant (MIC, >256 μg/ml). These data show the interspecies function of lsa and show a marked increase in the MICs of CLI and DAL and a moderate increase in the MIC of Q-D when it is introduced into E. faecium strains susceptible to these antibiotics. Bozdogan and Leclercq (5) also noted the influence of an LSA phenotype in E. faecium on Q-D MICs, where introduction of the sat(A) or vgb gene into a Q-D-susceptible E. faecium strain with the LSA phenotype conferred resistance to Q-D while, in contrast, introduction of these genes into another E. faecium strain susceptible to lincosamide, streptogramin A, and streptogramin B resulted in a 1- or 2-dilution increase in the MIC of Q-D (5).

View this table:
  • View inline
  • View popup
TABLE 3.

Susceptibility of E. faecalis and E. faecium strains to CLI and streptogramins

View this table:
  • View inline
  • View popup
TABLE 4.

MICs for E. faecium strains with and without lsa

Distribution of lsa among Enterococcus spp.Under high-stringency conditions, hybridization of colony lysates of 369 enterococci showed that lsa was present in all 180 E. faecalis isolates but not in 189 other enterococcal isolates (data not shown). Although most of our isolates were of human origin and animal isolates may differ, these results suggest that lsa is species specific for E. faecalis and may be an intrinsic gene of this species.

Characterization of lsa.The 2-kb region used for complementation, consisting of the 1,497-bp ORF of lsa, ∼300 bp upstream, and ∼200 bp downstream, was analyzed. The predicted Lsa protein (498 amino acids [aa]) showed similarities to known or postulated ABC proteins of other gram-positive bacteria [64% similarity to YjcA (513 aa) of Lactococcus lactis (4), 42% similarity to MsrC (493 aa) of E. faecium (44), and ca. 41% similarity to Vga(A) (523 aa) (1), Vga(B) (2), and Msr(A) (38) of Staphylococcus aureus (Fig. 1 )]. ABC transporters usually contain four single or joined components that are arranged into two homologous halves, each containing an ATP-binding domain and a membrane-spanning domain composed of several (usually six) putative α-helical transmembrane segments (9, 16, 17, 41). In the case of Msr(A), the two ATP-binding regions are fused into a single protein with internally homologous domains while in other instances, the ATP-binding regions are monomeric and likely form dimers in vivo (9, 22, 24, 41). ABC-type ATPase characteristic features, including a putative ABC signature sequence and the Walker A and B motifs, as reported in the literature for Msr(A), Vga(A), and Vga(B) (1, 2, 37), were identified in the corresponding regions of Lsa (Fig. 1). Hydropathy analysis of Lsa with the TMAP and Tmpred website programs revealed no transmembrane helix or a single strong transmembrane helix, respectively. This is similar to Msr(A), which contains no hydrophobic stretches that might be potential membrane-spanning domains, and it remains unclear for Msr(A) whether it utilizes hydrophobic proteins encoded by the genes smpA, smpB, and smpC mapping on the staphylococcal chromosome (37). Genes encoding other ABC proteins that contain two ATP-binding domains but no hydrophobic domain in gram-positive organisms include lmrC, a lincomycin resistance gene from Streptomyces lincolnensis (33); oleB, an oleandomycin resistance gene from S. antibioticus (32); srmB, a spiramycin resistance gene from S. ambofaciens (15); and a tylosin resistance gene from S. fradiae (39). A 45-aa putative peptide was also identified preceding the lsa start codon; the presence of this sequence seems to be important for the expression of drug resistance, as attempts to complement the disruption mutant with only cloned lsa failed to restore resistance to CLI, Q-D, and DAL. The presence of leader peptide sequences for msr(A), erm(A), erm(B), and erm(C) has been reported or postulated to be involved in posttranscriptional regulation of the expression of these resistance genes (6, 11, 21, 24, 34, 38, 45).

  • Open in new tab
  • Download powerpoint
  • Open in new tab
  • Download powerpoint
FIG. 1.

Multiple-sequence alignment of Lsa, Msr(A), Msr(C), Vga(A), Vga(B), and YjcA. ClustalW, at the Baylor College of Medicine website, was used, and the GeneDoc software was used for editing and shading. Shown are the two ATP-binding domains, consisting of Walker A and B motifs (underlined) and an SGG sequence (underlined). The bottom line shows the consensus sequence. Regions in which the six proteins are 100% identical are marked in solid black, dark gray shows regions >80% identical, and light gray shows regions with >60% identical amino acids.

In conclusion, we have shown the importance of the lsa gene of E. faecalis for the intrinsic LSA phenotype (CLI and DAL resistance) and Q-D resistance of this species. The apparent species specificity of lsa also suggests that it may be useful for the identification of E. faecalis isolates. We did not study efflux, but Lsa showed sequence similarities to known and postulated ABC transporters, including Msr(A), Vga(A), and Vga(B), suggesting that the protection of E. faecalis against CLI and DAL may be related to ATP-energized efflux of these antibiotics. We have also shown that lsa is functional in isolates of E. faecium and increases the MICs of CLI, DAL, and/or Q-D to various degrees, depending on the initial host's level of susceptibility to these agents.

ACKNOWLEDGMENTS

This work was supported, in part, by USPHS grant AI47923 to Barbara E. Murray from the Division of Microbiology and Infectious Diseases of the National Institutes of Health.

FOOTNOTES

    • Received 24 October 2001.
    • Returned for modification 29 January 2002.
    • Accepted 21 March 2002.
  • Copyright © 2002 American Society for Microbiology

REFERENCES

  1. 1.↵
    Allignet, J., V. Loncle, and N. El Sohl. 1992. Sequence of a staphylococcal plasmid gene, vga, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics. Gene117:45-51.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Allignet, J., and N. El Sohl. 1997. Characterization of a new staphylococcal gene, vgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. Gene202:133-138.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Allington, D. R., and M. P. Rivey. 2001. Quinupristin/dalfopristin: a therapeutic review. Clin. Ther23:24-44.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Bolotin, A., P. Wincker, S. Mauger, O. Jaillon, K. Malarme, J. Weissenbach, S. D. Ehrlich, and A. Sorokin. 2001. The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL-1403. Genome Res.11:731-753.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Bozdogan, B., and R. Leclercq. 1999. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium. Antimicrob. Agents Chemother.43:2720-2725.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Brisson-Noel, A., M. Arthur, and P. Courvalin. 1988. Evidence for natural gene transfer from gram-positive cocci to Escherichia coli. J. Bacteriol.170:1739-1745.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Coque, T. M., J. F. Tomayko, S. C. Ricke, P. O. Okhuysen, and B. E. Murray. 1996. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob. Agents Chemother.40:2605-2609.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Davis, D. R., J. B. McAlpine, C. J. Pazoles, M. K. Talbot, E. A. Alder, C. White, B. M. Jonas, B. E. Murray, G. M. Weinstock, and B. L. Rogers. 2001. Enterococcus faecalis multi-drug resistance transporters: application for antibiotic discovery. J. Mol. Microbiol. Biotechnol.3:179-184.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Dean, M., and R. Allikmets. 1995. Evolution of ATP-binding cassette transporter genes. Curr. Opin. Genet. Dev.5:779-785.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Delgado, G. J., M. M. Neuhauser, D. T. Bearden, and L. H. Danziger. 2000. Quinupristin-dalfopristin: an overview. Pharmacotherapy20:1469-1485.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Dubnau, D. 1984. Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. Crit. Rev. Biochem.16:103-132.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Duh, R. W., K. V. Singh, K. Malathum, and B. E. Murray. 2001. In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. Microb. Drug Resist.7:39-46.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Fogg, G. C., C. M. Gibson, and M. G. Caparon. 1994. The identification of rofA, a positive-acting regulatory component of prtF expression: use of a mγδ-based shuttle mutagenesis strategy in Streptococcus pyogenes. Mol. Microbiol.11:671-684.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Friesenegger, A., S. Fiedler, L. A. Devriese, and R. Wirth. 1991. Genetic transformation of various species of Enterococcus by electroporation. FEMS Microbiol. Lett.63:323-327.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Geistlich, M., R. Losick, J. R. Turner, and R. N. Rao. 1992. Characterization of a novel regulatory gene governing the expression of a polyketide synthase gene in Streptomyces ambofaciens. Mol. Microbiol.6:2019-2029.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Hendrik, W. V., K. Venema, H. Bolhuis, I. Oussenko, J. Kok, B. Poolman, A. J. M. Driessen, and W. N. Konings. 1996. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc. Natl. Acad. Sci. USA93:10668-10672.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Hyde, S. C., P. Emsley, M. J. Hartshorn, M. M. Mimmack, U. Gileadi, S. R. Pearce, M. P. Gallagher, D. R. Gill, R. E. Hubbard, and C. F. Higgins. 1990. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature346:362-365.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother.35:1267-1272.
    OpenUrlFREE Full Text
  19. 19.↵
    Leclercq, R., and P. Courvalin. 1991. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother.35:1273-1276.
    OpenUrlFREE Full Text
  20. 20.↵
    Li, X., G. M. Weinstock, and B. E. Murray. 1995. Generation of auxotroph mutants of Enterococcus faecalis. J. Bacteriol.177:6866-6873.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Matsuoka, M., L. Janosi, K. Endou, and Y. Nakajima. 1999. Cloning and sequences of inducible and constitutive macrolide resistance genes in Staphylococcus aureus that correspond to an ABC transporter. FEMS Microbiol. Lett.181:91-100.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    Milton, I. D., C. L. Hewitt, and C. R. Harwood. 1992. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus. FEMS Microbiol. Lett.76:141-147.
    OpenUrlPubMed
  23. 23.↵
    Montecalvo, M. A., H. Horowitz, C. Gedris, C. Carbonaro, F. C. Tenover, A. Issah, P. Cook, and G. P. Wormser. 1994. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother.38:1363-1367.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Murphy, E. 1985. Nucleotide sequence of ermA, a macrolide-lincosamide-streptogramin B determinant in Staphylococcus aureus. J. Bacteriol.162:633-640.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    Murray, B. E. 1998. Diversity among multidrug-resistant enterococci. Emerg. Infect. Dis.4:37-47.
    OpenUrlPubMedWeb of Science
  26. 26.
    Murray, B. E. 1990. The life and times of the enterococcus. Clin. Microbiol. Rev.3:46-65.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med.342:710-721.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Murray, B. E., K. V. Singh, J. D. Heath, B. Sharma, and G. M. Weinstock. 1990. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J. Clin. Microbiol.28:2059-2063.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Murray, B. E., K. V. Singh, R. P. Ross, J. D. Heath, G. M. Dunny, and G. M. Weinstock. 1993. Generation of restriction map of Enterococcus faecalis strain OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol.175:5216-5223.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—fifth edition; approved standard. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  31. 31.↵
    National Committee for Clinical Laboratory Standards. 2000. Performance standard for antimicrobial susceptibility testing; tenth informational supplement (aerobic dilution). NCCLS document M100-S10. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  32. 32.↵
    Olano, C., A. M. Rodriguez, C. Mendez, and J. A. Salas. 1995. A second ABC transporter is involved in oleandomycin resistance and its secretion by Streptomyces antibioticus. FEMS Microbiol. Lett.16:333-343.
    OpenUrlCrossRef
  33. 33.↵
    Peschke, U., H. Schmidt, H. Z. Zhang, and W. Pipersberg. 1995. Molecular characterization of the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11. Mol. Microbiol.16:1137-1156.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    Projan, S. J., M. Monod, C. S. Narayanan, and D. Dubnau. 1987. Replication properties of pJM13, a naturally occurring plasmid found in Bacillus subtilis, and of its close relative pE5, a plasmid native to Staphylococcus aureus. J. Bacteriol.169:5131-5139.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Rende-Fournier, R., R. Leclercq, M. Galimand, J. Duval, and P. Courvalin. 1993. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob. Agents Chemother.37:2119-2125.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Rice, L. B., L. L. Carias, H.-T. R., F. Sifaoui, L. Gutmann, and S. D. Rudin. 2001. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother.45:1480-1486.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Ross, J. I., E. A. Eady, J. H. Cove, and S. Baumberg. 1995. Identification of a chromosomally encoded ABC-transport system with which the staphylococcal erythromycin exporter MsrA may interact. Gene153:93-98.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Ross, J. I., E. A. Eady, J. H. Cove, W. J. Cunliffe, S. Baumberg, and J. C. Wootton. 1990. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol. Microbiol.4:1207-1214.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    Rosteck, P. R. J., P. A. Reynolds, and C. L. Hershberger. 1991. Homology between proteins controlling Streptomyces fradiae tylosin resistance and ATP-binding transport. Gene102:27-32.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    Sahm, D. F., J. Kissinger, J. S. Gilmore, P. R. Murray, R. Mulder, J. Solliday, and B. Clarke. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother.33:1588-1591.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Saier, M. H. J., I. T. Paulsen, M. K. Sliwinski, S. S. Pao, R. A. Skurray, and H. Nikaido. 1998. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J.12:265-274.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  43. 43.↵
    Singh, K. V., T. M. Coque, G. M. Weinstock, and B. E. Murray. 1998. In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol. Med. Microbiol.21:323-331.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Singh, K. V., K. Malathum, and B. E. Murray. 2001. Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. Antimicrob. Agents Chemother.45:263-266.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Weisblum, B. 1985. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression—a review. J. Antimicrob. Chemother.16(Suppl.A):63-90.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    Wilson, K. 1994. Preparation of genomic DNA from bacteria, p. 2.4.1-2.4.2. In F. M. Ausubel, R. Brent, R. E. Kingston, D. M. David, J. G. Scidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Green Publishing Associates, Brooklyn, N.Y.
  47. 47.↵
    Wirth, R., F. An, and D. B. Clewell. 1987. Highly efficient cloning system for Streptococcus faecalis: protoplast transformation, shuttle vectors, and applications, p. 25-27. In J. J. Ferretti and R. Curtiss III (ed.), Streptococcal genetics. American Society for Microbiology, Washington, D.C.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin
Kavindra V. Singh, George M. Weinstock, Barbara E. Murray
Antimicrobial Agents and Chemotherapy Jun 2002, 46 (6) 1845-1850; DOI: 10.1128/AAC.46.6.1845-1850.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin
Kavindra V. Singh, George M. Weinstock, Barbara E. Murray
Antimicrobial Agents and Chemotherapy Jun 2002, 46 (6) 1845-1850; DOI: 10.1128/AAC.46.6.1845-1850.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS AND DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
clindamycin
Drug Therapy, Combination
Enterococcus faecalis
Genes, Bacterial
Virginiamycin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596